RxDoctor Payments Data

Yasmina Abajas

Chapel Hill, NCNPI 1063654259

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $85,023 of the $116,886 with a category attached, or 72.7%. 9 manufacturers reported payments, led by Sanofi at 36.0% of the total. 2025 is the largest year on record at $31,523, 6.9 times the $4,570 reported in 2019.

$116,886in general payments, 2019–2025

Across 103 payments — averaging $1134.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$42K
  • Genentech USA, Inc.$32K
  • Pfizer$14K
  • HEMA Biologics, LLC$12K
  • Sanofi US Services Inc.$11K
  • Bioverativ Therapeutics Inc.$3K
  • plus $3K from 3 others
$53,845in research payments, 2019–2025

Across 176 payments — averaging $305.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Daiichi Sankyo Inc.$53K
  • Grifols Therapeutics LLC$750

What the payments were for

  • Consulting fees$85,02373%
  • Speaking & faculty fees$17,85515%
  • Travel & lodging$10,7439%
  • Food & beverage$3,2523%
  • Education$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →